🎉 M&A multiples are live!
Check it out!

Guizhou Sanli Valuation Multiples

Discover revenue and EBITDA valuation multiples for Guizhou Sanli and similar public comparables like Vivoryon Therapeutics, Galapagos, and Pharming.

Guizhou Sanli Overview

About Guizhou Sanli

Guizhou Sanli Pharmaceutical Co Ltd is engaged in Chinese pharmaceutical research, development, production and marketing. The company produces and sells soft capsules, hard capsules, sprays (including Chinese medicine extraction) and provides Chinese medicine science and technology consulting services. Its products include Pediatric medication; Respiratory system medication; Cardiovascular and cerebrovascular drugs; Digestive medicine; Trauma injury medication; Rehabilitation medicine; and Ophthalmic medicine.


Founded

1995

HQ

China
Employees

n/a

Website

gz-sanli.com

Financials

LTM Revenue $312M

LTM EBITDA n/a

EV

$709M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Guizhou Sanli Financials

Guizhou Sanli has a last 12-month revenue of $312M and a last 12-month EBITDA of n/a.

In the most recent fiscal year, Guizhou Sanli achieved revenue of $225M and an EBITDA of $51.7M.

Guizhou Sanli expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Guizhou Sanli valuation multiples based on analyst estimates

Guizhou Sanli P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $225M $297M XXX XXX XXX
Gross Profit $91.2M $119M XXX XXX XXX
Gross Margin 40% 40% XXX XXX XXX
EBITDA $51.7M n/a XXX XXX XXX
EBITDA Margin 23% NaN% XXX XXX XXX
Net Profit $21.0M $27.7M XXX XXX XXX
Net Margin 9% 9% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Guizhou Sanli Stock Performance

As of April 15, 2025, Guizhou Sanli's stock price is CNY 13 (or $2).

Guizhou Sanli has current market cap of CNY 5.2B (or $711M), and EV of CNY 5.1B (or $709M).

See Guizhou Sanli trading valuation data

Guizhou Sanli Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$709M $711M XXX XXX XXX XXX $0.12

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Guizhou Sanli Valuation Multiples

As of April 15, 2025, Guizhou Sanli has market cap of $711M and EV of $709M.

Guizhou Sanli's trades at 2.3x LTM EV/Revenue multiple, and n/a LTM EBITDA.

Analysts estimate Guizhou Sanli's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Guizhou Sanli and 10K+ public comps

Guizhou Sanli Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $709M XXX XXX XXX
EV/Revenue 2.4x XXX XXX XXX
EV/EBITDA n/a XXX XXX XXX
P/E 15.3x XXX XXX XXX
P/E/Growth 0.9x XXX XXX XXX
EV/FCF n/a XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Guizhou Sanli Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Guizhou Sanli Valuation Multiples

Guizhou Sanli's NTM/LTM revenue growth is 17%

Guizhou Sanli's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.

Over next 12 months, Guizhou Sanli's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Guizhou Sanli's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Guizhou Sanli and other 10K+ public comps

Guizhou Sanli Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth 32% XXX XXX XXX XXX
EBITDA Margin n/a XXX XXX XXX XXX
EBITDA Growth n/a XXX XXX XXX XXX
Rule of 40 (SaaS-only) n/a XXX XXX XXX XXX
Revenue per Employee n/a XXX XXX XXX XXX
Opex per Employee n/a XXX XXX XXX XXX
S&M Expenses to Revenue 40% XXX XXX XXX XXX
G&A Expenses to Revenue 2% XXX XXX XXX XXX
R&D Expenses to Revenue 2% XXX XXX XXX XXX
Opex to Revenue 56% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Guizhou Sanli Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Guizhou Sanli M&A and Investment Activity

Guizhou Sanli acquired  XXX companies to date.

Last acquisition by Guizhou Sanli was  XXXXXXXX, XXXXX XXXXX XXXXXX . Guizhou Sanli acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Guizhou Sanli

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Guizhou Sanli

When was Guizhou Sanli founded? Guizhou Sanli was founded in 1995.
Where is Guizhou Sanli headquartered? Guizhou Sanli is headquartered in China.
Is Guizhou Sanli publicy listed? Yes, Guizhou Sanli is a public company listed on SHG.
What is the stock symbol of Guizhou Sanli? Guizhou Sanli trades under 603439 ticker.
When did Guizhou Sanli go public? Guizhou Sanli went public in 2020.
Who are competitors of Guizhou Sanli? Similar companies to Guizhou Sanli include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Guizhou Sanli? Guizhou Sanli's current market cap is $711M
What is the current revenue of Guizhou Sanli? Guizhou Sanli's last 12-month revenue is $312M.
What is the current EV/Revenue multiple of Guizhou Sanli? Current revenue multiple of Guizhou Sanli is 2.3x.
What is the current revenue growth of Guizhou Sanli? Guizhou Sanli revenue growth between 2023 and 2024 was 32%.
Is Guizhou Sanli profitable? Yes, Guizhou Sanli is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.